Canada markets closed
  • S&P/TSX

    20,154.54
    -335.82 (-1.64%)
     
  • S&P 500

    4,357.73
    -75.26 (-1.70%)
     
  • DOW

    33,970.47
    -614.41 (-1.78%)
     
  • CAD/USD

    0.7811
    +0.0005 (+0.07%)
     
  • CRUDE OIL

    70.64
    +0.35 (+0.50%)
     
  • BTC-CAD

    55,053.06
    -5,783.06 (-9.51%)
     
  • CMC Crypto 200

    1,076.57
    -57.81 (-5.10%)
     
  • GOLD FUTURES

    1,765.80
    +2.00 (+0.11%)
     
  • RUSSELL 2000

    2,182.20
    -54.67 (-2.44%)
     
  • 10-Yr Bond

    1.3090
    -0.0610 (-4.45%)
     
  • NASDAQ futures

    14,999.00
    -10.50 (-0.07%)
     
  • VOLATILITY

    25.71
    +4.90 (+23.55%)
     
  • FTSE

    6,903.91
    -59.73 (-0.86%)
     
  • NIKKEI 225

    30,500.05
    +176.75 (+0.58%)
     
  • CAD/EUR

    0.6656
    +0.0008 (+0.12%)
     

CRMD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 20, 2021 in the Class Action Filed on Behalf of CorMedix Inc. Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - September 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CorMedix Inc. (NASDAQ: CRMD) alleging that the Company violated federal securities laws.

Class Period: October 16, 2019 and May 13, 2021
Lead Plaintiff Deadline: September 20, 2021
No obligation or cost to you.

Learn more about your recoverable losses in CRMD:
https://www.kleinstocklaw.com/pslra-1/cormedix-inc-loss-submission-form?id=19597&from=5

CorMedix Inc. NEWS - CRMD NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in CorMedix you have until September 20, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased CorMedix securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the CRMD lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96653

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting